Keep pulling the thread on Novo Nordisk.
AI-powered drug development is projected to reduce the medicine creation timeline to between three and six years.
With AI-driven drug discovery, the success rate for drugs in Phase 1 human trials is projected to increase to 85%.
Artificial intelligence is projected to generate $110 billion in annual value for the pharmaceutical industry.
RENTOSERTIB is the first drug in history for which AI was used to discover both the biological target and the chemical compound.
Drugs discovered using AI are demonstrating an 80% to 90% success rate in early clinical trials.
Novo Nordisk has committed to a partnership related to AI drug discovery valued at nearly $2.8 billion.
Eli Lilly has entered into a partnership related to AI drug discovery valued at over $1.7 billion.
Traditionally, 52% of drugs successfully pass Phase 1 human trials.
Within the pharmaceutical industry, AI is expected to generate $35 billion in annual value specifically from drug discovery and development.
AI is projected to create $20 billion in annual value by improving the efficiency of clinical trials.
AI is expected to add $18 billion in annual value to pharmaceutical manufacturing processes.
Using AI, the drug RENTOSERTIB progressed from an initial concept to a preclinical candidate in 18 months.